Interstitial pneumonitis related to rituximab therapy for Waldenström's macroglobulinemia
Rituximab-combined therapeutic regimens have been recommended for treatment of Waldenström's Macroglobulinemia (WM). We report one WM patient who developed interstitial pneumonitis after rituximab therapy.
Main Authors: | Bai, Xueyan, Cui, Qu, Liu, Yuanbo |
---|---|
Format: | Online |
Language: | English |
Published: |
BlackWell Publishing Ltd
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352371/ |
Similar Items
-
Rituximab and Fludarabine or Cyclophosphamide Combination Treatment for Older Waldenström Macroglobulinemia Patients
by: Xu, XiaoWei, et al.
Published: (2013) -
Waldenstrom macroglobulinemia: prognosis and management
by: Oza, A, et al.
Published: (2015) -
How to manage Waldenstrom's macroglobulinemia
by: Buske, C, et al.
Published: (2013) -
Waldenstrom's macroglobulinemia associated with eosinophilia
by: You, Eunkyoung, et al.
Published: (2013) -
Pseudohyperphosphatemia in Waldenstrom's Macroglobulinemia
by: Amalnath, S. D., et al.
Published: (2013)